Eagle Pharmaceuticals, Inc.

Eagle reported Q2 2023 revenue of $64.6 million versus $74.1 million in Q2 2022, and net product sales of $43.0 million versus $49.2 million. Gross margin was 74% in Q2 2023 compared with 68% a year ago, and gross margin excluding amortization was 83% versus 70%. Net income was $5.2 million, or $0.39 per diluted share, versus a net loss of $9.5 million, or $0.74 per share, in the prior-year quarter; adjusted non-GAAP net income was $15.5 million, or $1.18 per share, and adjusted EBITDA was $20.7 million. PEMFEXY sales were $19.4 million, BELRAPZO sales were $6.8 million, RYANODEX sales were $10.0 million, Barhemsys and Byfavo sales were $1.2 million, and royalty revenue was $21.7 million. As of June 30, 2023, cash and cash equivalents were $15.4 million, net accounts receivable were $115.1 million, and outstanding debt was $71.3 million. Management said it recently raised full-year guidance, expects to end 2023 with over $100 million in net working capital, and anticipates roughly the same gross profit in 2023 as in 2022 excluding amortization.

Scott Tarriff framed the quarter as part of a strong 18-month run, citing fourth straight consensus beat, rising market share in PEMFEXY, and improving relaunch traction for Barhemsys and Byfavo. He emphasized that Eagle is investing in R&D and commercial infrastructure now so that future products can be added with minimal incremental cost. His tone was upbeat and confident, especially around the pipeline and the company’s ability to generate cash while investing.

Brian Cahill focused on the quarter’s financial bridge: revenue and product sales were lower year over year, but gross margin expanded meaningfully to 74% and gross margin excluding amortization reached 83%. He tied margin strength to higher PEMFEXY sales, the expiration of bendamustine royalty payments, and the PEMFEXY royalty buydown, while noting R&D was $9.8 million and SG&A was $27.7 million, both influenced by timing and prior acquisition costs. He also pointed to the balance sheet, with $15.4 million in cash, $115.1 million in net receivables, and $71.3 million in debt, alongside management’s expectation for strong working capital and continued positive cash flow.

Analysts asked about Q3 seasonality and gross margin drivers, and Cahill explained that RYANODEX is lumpy because sales depend on a 36-month shelf-life cycle, while margin improvement stems from the end of bendamustine royalties and the PEMFEXY royalty buydown. On Barhemsys and Byfavo, Tarriff said the company has only fully marketed them for two quarters, but sees the current ~30% sequential growth continuing for the foreseeable future. When asked about the weak share price, Tarriff said he did not know the disconnect from the market, but argued the business has been rebased, margins are growing, cash generation is strong, and additional products could be added with limited extra expense.